<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article article-type="research-article"><!-- Original-type: oa--><?properties no_embargo?><?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ajarticle_v7_x.dtd?><?SourceDTD.Version 7.0?><?ConverterInfo.XSLTName npg-specialarticle2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes Immun</journal-id><journal-title>Genes and Immunity</journal-title><issn pub-type="ppub">1466-4879</issn><issn pub-type="epub">1476-5470</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pii">gene2009101</article-id><article-id pub-id-type="doi">10.1038/gene.2009.101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>HLA-class I markers and multiple sclerosis susceptibility in the Italian population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bergamaschi</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leone</surname><given-names>M A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fasano</surname><given-names>M E</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Guerini</surname><given-names>F R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ferrante</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bolognesi</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barizzone</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Corrado</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Naldi</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Agliardi</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Dametto</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Salvetti</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Visconti</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Galimberti</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Scarpini</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Vercellino</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bergamaschi</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Monaco</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Caputo</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Momigliano-Richiardi</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>D'Alfonso</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Medical Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont</institution> Novara, <country>Italy</country></aff><aff id="aff2"><label>2</label><institution>Department of Neurology, Ospedale Maggiore and IRCAD</institution> Novara, <country>Italy</country></aff><aff id="aff3"><label>3</label><institution>Transplantation Immunology, San Giovanni Battista Hospital</institution> Turin, <country>Italy</country></aff><aff id="aff4"><label>4</label><institution>Laboratory of Molecular Medicine and Biotechnology, Don C Gnocchi Foundation IRCCS, S Maria Nascente</institution> Milan, <country>Italy</country></aff><aff id="aff5"><label>5</label><institution>Department of Medical Sciences, Unit of Medical Statistics and Cancer Epidemiology, University of Eastern Piedmont and CPO Piemonte</institution> Novara, <country>Italy</country></aff><aff id="aff6"><label>6</label><institution>Neurology and Center for Experimental Neurological Therapy (CENTERS), Universit&#x000e0; La Sapienza</institution> Roma, <country>Italy</country></aff><aff id="aff7"><label>7</label><institution>Department of Neurological Sciences, Dino Ferrari Center, University of Milan, Fondazione Ospedale Maggiore Policlinico</institution> Milan, <country>Italy</country></aff><aff id="aff8"><label>8</label><institution>Department of Neurology, Ospedale San Giovanni Battista</institution> Torino, <country>Italy</country></aff><aff id="aff9"><label>9</label><institution>Neurological Institute C Mondino, IRCCS</institution> Pavia, <country>Italy</country></aff><aff id="aff10"><label>10</label><institution>Department of Neurology, Ospedale Maggiore</institution> Novara, <country>Italy</country></aff><aff id="aff11"><label>11</label><institution>Department of Clinical and Experimental Medicine, University of Eastern Piedmont</institution> Novara, <country>Italy</country></aff><aff id="aff12"><label>12</label><institution>Multiple Sclerosis Unit, Don C Gnocchi Foundation, IRCCS, S Maria Nascente</institution> Milan, <country>Italy</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:dalfonso@med.unipmn.it">dalfonso@med.unipmn.it</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>11</month><year>2009</year></pub-date><pub-date pub-type="collection"><day>03</day><month>03</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>03</month><year>2010</year></pub-date><volume>11</volume><issue>2</issue><fpage>173</fpage><lpage>180</lpage><history><date date-type="received"><day>13</day><month>04</month><year>2009</year></date><date date-type="rev-recd"><day>22</day><month>09</month><year>2009</year></date><date date-type="accepted"><day>23</day><month>09</month><year>2009</year></date></history><copyright-statement>Copyright 2010, Macmillan Publishers Limited</copyright-statement><copyright-year>2010</copyright-year><permissions><copyright-holder>Macmillan Publishers Limited</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><p>This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Licence. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</p></license></permissions><abstract><p>Previous studies reported an association with multiple sclerosis (MS) of distinct HLA-class I markers, namely <italic>HLA-A&#x0002a;02</italic>, <italic>HLA-Cw&#x0002a;05</italic> and <italic>MOG-142L</italic>. In this work, we tested the association with MS of <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic> in 1273 Italian MS patients and 1075 matched controls, which were previously analyzed for <italic>MOG-142</italic>, and explored the relationship among these three markers in modulating MS risk. <italic>HLA-A&#x0002a;02</italic> conferred a statistically robust MS protection (odds ratio, OR=0.61; 95&#x00025; confidence intervals, CI=0.51&#x02013;0.72, <italic>P</italic>&#x0003c;10<sup>&#x02212;9</sup>), which was independent of <italic>DRB1&#x0002a;15</italic> and of any other <italic>DRB1&#x0002a;</italic> allele and remained similar after accounting for the other two analyzed class I markers. Conversely, the protective effect we previously observed for <italic>MOG-142L</italic> was secondary to its linkage disequilibrium with <italic>A&#x0002a;02</italic>. <italic>Cw&#x0002a;05</italic> was not associated considering the whole sample, but its presence significantly enhanced the protection in the <italic>HLA-A&#x0002a;02-</italic>positive group, independently of <italic>DRB1</italic>: the OR conferred by <italic>A&#x0002a;02</italic> in <italic>Cw&#x0002a;05-</italic>positive individuals (0.22, 95&#x00025; CI=0.13&#x02013;0.38) was significantly lower than in <italic>Cw&#x0002a;05-</italic>negative individuals (0.69, 95&#x00025; CI=0.58&#x02013;0.83) with a significant (<italic>P</italic>=4.94 &#x000d7; 10<sup>&#x02212;5</sup>) multiplicative interaction between the two markers. In the absence of <italic>A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic> behaved as a risk factor, particularly in combination with <italic>DRB1&#x0002a;03</italic> (OR=3.89, <italic>P</italic>=0.0006), indicating that <italic>Cw&#x0002a;05</italic> might be a marker of protective or risk haplotypes, respectively.</p></abstract><kwd-group><kwd>multiple sclerosis</kwd><kwd>HLA-class I markers</kwd><kwd>extended HLA haplotypes</kwd><kwd>Myelin Oligodendrocyte Glycoprotein</kwd><kwd>genetic association</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by disseminated and focal damage of myelin and axons, resulting in a disabling condition.<sup><xref ref-type="other" rid="bib1">1</xref></sup> The pathogenesis of MS is not understood yet, but several studies suggest an interaction of environmental and genetic factors.<sup><xref ref-type="other" rid="bib2">2</xref></sup> The genetic factor showing the strongest association with MS is localized in the human Major Histocompatibility complex (HLA) region on chromosome 6p21.3. The risk haplotype that has been identified for the Caucasian populations is <italic>HLA DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> (also known as <italic>DR15</italic> haplotype) in the HLA-class II region. In the Italian<sup><xref ref-type="other" rid="bib3">3</xref></sup> as well as in other European populations,<sup><xref ref-type="other" rid="bib4">4</xref>, <xref ref-type="other" rid="bib5">5</xref>, <xref ref-type="other" rid="bib6">6</xref></sup><italic>DR15</italic> confers an odds ratio (OR) of about 3.</p><p>In recent years, several studies have searched for the presence of MS susceptibility factors in the HLA region with an effect independent of <italic>HLA-DRB1.</italic> No evidence of an HLA-A or -B association was found by Chao <italic>et al.</italic><sup><xref ref-type="other" rid="bib7">7</xref></sup> in 294 Canadian families. Moreover, none of the 1068 single-nucleotide-polymorphisms (SNPs) from a high-density panel spanning the entire HLA genomic region showed additional association in 1185 Canadian and Finnish families after conditioning for <italic>HLA-DRB1.</italic><sup><xref ref-type="other" rid="bib8">8</xref></sup> Conversely, other studies have detected the effect at least of one class I genetic factor independently of <italic>HLA-DRB1</italic>. Brynedal <italic>et al.</italic><sup><xref ref-type="other" rid="bib9">9</xref></sup> confirmed in a Nordic cohort of 1084 MS patients and 1347 controls the results of a previous study performed in a smaller Swedish panel,<sup><xref ref-type="other" rid="bib10">10</xref></sup> showing that HLA-A<sup>&#x0002a;</sup>02 is negatively associated with MS (OR=0.63, <italic>P</italic>=7 &#x000d7; 10<sup>&#x02212;12</sup>). Yeo <italic>et al.</italic><sup><xref ref-type="other" rid="bib11">11</xref></sup> analyzed over 1600 UK MS patients and 3600 controls and found that <italic>HLA-Cw&#x0002a;05</italic> exerts an MS-protective effect (OR=0.49, 95&#x00025; confidence intervals, CI=0.34&#x02013;0.69, <italic>P</italic>=3.3 &#x000d7; 10<sup>&#x02212;5</sup>) after excluding all individuals carrying <italic>DRB1</italic> alleles associated with MS. In a panel of 1124 Italian MS patients and 1136 controls, we found a significant association with the missense variant <italic>V142L</italic> (rs2857766) in the gene encoding the Myelin Oligodendrocyte Glycoprotein (MOG) mapping in the HLA-class I region, telomeric to <italic>HLA-A</italic> (0.3&#x02009;Mb) and <italic>HLA-C</italic> (1.6&#x02009;Mb).<sup><xref ref-type="other" rid="bib12">12</xref></sup> The <italic>142L</italic> allele (<italic>MOG-142L)</italic> conferred an OR=0.70 (95&#x00025; C.I=0.60&#x02013;0.82) that remained similar after accounting for <italic>HLA</italic>-<italic>DRB1&#x0002a;15</italic> carrier status.<sup><xref ref-type="other" rid="bib12">12</xref></sup> Burfoot <italic>et al.</italic><sup><xref ref-type="other" rid="bib13">13</xref></sup> showed similar data in a small Tasmanian population. Moreover, they reported a negative association with <italic>HLA-A&#x0002a;02</italic>, but they did not analyze if this variation was primarily associated or was dependent on <italic>MOG-142L</italic>.<sup><xref ref-type="other" rid="bib13">13</xref></sup></p><p>The relationship among the three reported HLA-class I markers, <italic>A&#x0002a;02</italic>, <italic>Cw&#x0002a;05, MOG-142L</italic> and their association with MS has not been examined so far.</p><p>In this work, we tested the association of <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic> in a large cohort of Italian MS patients and controls, most of whom had been previously typed for <italic>MOG-142</italic> polymorphism, and we explored the relationship among <italic>MOG-142L</italic>, <italic>HLA-A&#x0002a;02</italic> and <italic>HLA-Cw&#x0002a;05</italic> in modulating MS risk.</p></sec><sec><title>Results</title><sec><title>Association with MS of MOG-142L, HLA-A<sup>&#x0002a;</sup>02 and HLA-Cw<sup>&#x0002a;</sup>05 in the Italian population</title><p>The MS association of <italic>MOG-142L</italic>, <italic>HLA-A&#x0002a;02</italic> and <italic>HLA-Cw&#x0002a;05</italic> was tested in a case&#x02013;control study (<xref rid="tbl1" ref-type="table">Table 1</xref>). The frequency of <italic>MOG-142L</italic> and <italic>HLA-A&#x0002a;02-</italic>positive individuals was significantly lower in cases than in controls, confirming the previously reported protective effect,<sup><xref ref-type="other" rid="bib9">9</xref>, <xref ref-type="other" rid="bib10">10</xref>, <xref ref-type="other" rid="bib12">12</xref>, <xref ref-type="other" rid="bib13">13</xref></sup> whereas the association with <italic>Cw&#x0002a;05</italic> was not significant. The comparison of genotype frequencies suggested a dominant-protective effect of <italic>MOG-142L</italic> and of <italic>HLA-A&#x0002a;02</italic>, as their frequency was significantly decreased both among homozygous (OR=0.55, 95&#x00025; CI=0.34&#x02013;0.89 for <italic>142L</italic> and OR=0.55, 95&#x00025; CI=0.37&#x02013;0.82 for <italic>A&#x0002a;02</italic>) and heterozygous (OR=0.75, 95&#x00025; CI=0.62&#x02013;0.90 for <italic>142L</italic> and OR=0.68, 95&#x00025; CI=0.57&#x02013;0.81 for <italic>A&#x0002a;02</italic>) MS patients. The results did not change after adjustment for sex and were not different among male and female cases in a stratified analysis (data not shown). The results were not significantly different in relapsing remitting and primary progressive patients (data not shown).</p><p>To eliminate the possible confounding effect of linkage disequilibrium (LD) with <italic>HLA-DRB1&#x0002a;15</italic>, we performed the same analysis in <italic>DRB1&#x0002a;15-</italic>negative individuals. The OR values for the three tested markers remained substantially the same (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>The relative effect of the three tested HLA-class I markers on MS risk was evaluated by logistic regression analysis (<xref rid="tbl2" ref-type="table">Table 2</xref>). <italic>DRB1&#x0002a;15</italic> was also included in the model. All individuals were categorized according to the presence or absence of each of the four considered alleles. The OR conferred by <italic>A&#x0002a;02</italic> remained similar after accounting for each of the other markers included in the model and for all the markers together, showing that the protective effect was independent of any other analyzed HLA marker. Conversely, the protective effect of <italic>MOG-142L</italic> was abolished by adjustment for <italic>A&#x0002a;02</italic>. The lack of a significant association with <italic>Cw&#x0002a;05</italic> and the significant risk effect of <italic>DRB1&#x0002a;15</italic> were similar with and without the adjustment for the remaining markers. This analysis clearly showed that the association with <italic>MOG-142L</italic> was not independent of <italic>HLA-A&#x0002a;02</italic>. This was also indicated by an analysis stratified for <italic>HLA-A&#x0002a;02</italic>: <italic>MOG-142L</italic> was not significantly associated either in the <italic>A&#x0002a;02</italic> positive (OR=0.96 95&#x00025; CI=0.74&#x02013;1.23, <italic>P</italic>=0.76) or in the <italic>A&#x0002a;02</italic> negative (OR=0.80, 95&#x00025; CI=0.60&#x02013;1.07, <italic>P</italic>=0.13). These results were explained by the strong LD (<italic>D</italic>&#x02032;=0.59; <italic>r</italic><sup>2</sup>=0.5) between the two alleles both in the control and in the MS patient population (<xref rid="tbl3" ref-type="table">Table 3</xref>).</p><p>Considerable LD was also detected between <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic> in the control population (<xref rid="tbl3" ref-type="table">Table 3</xref>). Notably, it was completely absent in the MS patients. This difference was explained by the significantly decreased frequency of the <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b; phenotypic combination in the MS patient as opposed to the control population (<xref rid="tbl4" ref-type="table">Table 4</xref>). When analyzing in more detail the effect of the different phenotypic combinations of the <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic> alleles on MS risk (<xref rid="tbl4" ref-type="table">Table 4</xref>), it appeared that the <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b; combination conferred an OR (0.38) significantly lower than that (OR=0.73) consequent to the presence of <italic>A&#x0002a;02</italic> in the absence of <italic>Cw&#x0002a;05</italic>. Conversely, in the absence of <italic>HLA-A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic> showed a significant positive association with MS (OR=1.85). The same results were seen when considering only <italic>DRB1&#x0002a;15-</italic>negative individuals (<xref rid="tbl4" ref-type="table">Table 4</xref>).</p><p>Stratification for the <italic>HLA-Cw&#x0002a;05</italic> revealed a substantial difference in risk conferred by the <italic>A&#x0002a;02</italic> among <italic>Cw&#x0002a;05-</italic>positive individuals (OR=0.22, 95&#x00025; CI=0.13&#x02013;0.38) and <italic>Cw&#x0002a;05-</italic>negative individuals (OR=0.69, 95&#x00025; CI=0.58&#x02013;0.83). When stratifying for <italic>A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic> behaved as a protective factor among <italic>A&#x0002a;02-</italic>positive individuals (OR=0.50, 95&#x00025; CI=0.33&#x02013;0.74) and as a risk factor among <italic>A&#x0002a;02-</italic>negative individuals (OR=1.53, 95&#x00025; CI=1.04&#x02013;2.24). The likelihood ratio test used to compare the full model (including the two markers and the interaction term) to the additive model (including only the two markers) was statistically significant (<italic>P</italic>=4.9 &#x000d7; 10<sup>&#x02212;5</sup>). Thus, although <italic>HLA-Cw&#x0002a;05</italic> and <italic>A&#x0002a;02</italic> are not reciprocally confounders, as there was no difference between <italic>crude</italic> and <italic>adjusted</italic> ORs (<xref rid="tbl2" ref-type="table">Table 2</xref>), the stratification analysis showed a significant multiplicative interaction between the two markers.</p><p>From the analysis in the case&#x02013;control population, it was not possible to distinguish whether the <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b; individuals carried the two alleles in <italic>cis</italic> or in <italic>trans</italic>. We, therefore, analyzed the transmission of these two alleles in 201 family trios. No Mendelian errors were observed. Notably, out of 10 haplotypes that carried both <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic>, none were transmitted to the MS patients (T:NT=0:10; <italic>P</italic>=0.002). The only <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b; MS patient present in this panel inherited the two alleles in trans. <italic>A&#x0002a;02-</italic>positive individuals of the family trios were sequenced to define the <italic>A&#x0002a;02</italic> alleles at a higher resolution. In agreement with the literature (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.allelefrequencies.net/">http://www.allelefrequencies.net/</ext-link>), in these samples, <italic>A&#x0002a;0201</italic> was the most frequent <italic>A&#x0002a;02</italic> allele (90&#x00025;) followed by <italic>A&#x0002a;0205</italic> (8&#x00025;) and <italic>A&#x0002a;0217</italic> (2&#x00025;). <italic>A&#x0002a;0201</italic> was the most represented <italic>A&#x0002a;02</italic> allele both in the <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b; and in the <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x02212; haplotypes. The same proportion of <italic>A&#x0002a;02</italic> subtypes was seen among transmitted and non-transmitted haplotypes (data not shown).</p><p>The joint effect of class I (<italic>A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic>) and class II (<italic>DRB1&#x0002a;15</italic>) markers on MS risk is reported in <xref ref-type="fig" rid="fig1">Figure 1</xref>. All the combinations of these three alleles showed a significantly increased risk relative to the <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b;, <italic>DRB1&#x0002a;15</italic>&#x02212; phenotype, which is characterized both by the presence of the class I markers conferring the highest protection and by the absence of the class II allele conferring the highest risk. The three combinations carrying <italic>DRB1&#x0002a;15</italic> in the absence of the highly protective <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b; phenotype (that is carrying only <italic>A&#x0002a;02</italic> or only <italic>Cw&#x0002a;05</italic> or none of them) showed a similar eightfold increased risk. In the presence of both <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic>, the <italic>DRB1&#x0002a;15</italic> risk approximately halved to 4.57, although this difference was not statistically significant owing to the low frequency of this phenotype (<italic>N</italic>=13 MS patients and 8 controls). In the absence of <italic>DRB1&#x0002a;15</italic>, a differently increased risk was observed according to the presence of only <italic>A&#x0002a;02</italic> (OR=2.11) or only <italic>Cw&#x0002a;05</italic> (OR=5.47) or none of them (OR=3.14).</p></sec><sec><title>Stratification for DRB1 alleles</title><p>To test whether the detected associations were consequent on LD with <italic>DRB1</italic> alleles different from <italic>DRB1&#x0002a;15</italic>, we evaluated the relationship of <italic>HLA-A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic> and their combinations with the <italic>DRB1</italic> locus in a random subset of 562 MS cases and 888 controls fully typed for <italic>DRB1</italic> at low resolution. In this subgroup, <italic>DRB1&#x0002a;15</italic> was positively MS associated with OR=2.86 (95&#x00025; CI=2.14&#x02013;3.83; <italic>P</italic>=8.4 &#x000d7; 10<sup>&#x02212;14</sup>). When considering <italic>DRB1&#x0002a;15-</italic>negative individuals, there was an additional significantly positive association with <italic>DRB1&#x0002a;04</italic> (OR=1.88, 95&#x00025; CI=1.34&#x02013;2.63, <italic>P</italic>=1.6 &#x000d7; 10<sup>&#x02212;4</sup>) and a negative association with <italic>DRB1&#x0002a;07</italic> of borderline significance (OR=0.69, 95&#x00025; CI=0.49&#x02013;0.98, <italic>P</italic>=0.036). At variance with other studies, <italic>DRB1&#x0002a;03</italic> was not associated (OR=1.0, 95&#x00025; CI=0.72&#x02013;1.39). A modest global LD was detected between <italic>HLA-A&#x0002a;02</italic> and <italic>DRB1</italic> (Global <italic>D</italic>&#x02032;=0.149, Cramer's <italic>V</italic>=0.176) and between <italic>HLA-Cw&#x0002a;05</italic> and <italic>DRB1</italic> (Global <italic>D</italic>&#x02032;=0.280, Cramer's <italic>V</italic>=0.194). The association with <italic>A&#x0002a;02</italic> remained significant after conditioning on the <italic>DRB1</italic> locus by the COCAPHASE program (unconditioned <italic>P</italic>=1.9 &#x000d7; 10<sup>&#x02212;5</sup>; conditioned <italic>P</italic>=2.2 &#x000d7; 10<sup>&#x02212;4</sup>), thus showing that it is independent of <italic>DRB1</italic>. <italic>Cw&#x0002a;05</italic> was not significantly associated (unconditioned <italic>P</italic>=0.09; conditioned <italic>P</italic>=0.19). The OR conferred by <italic>HLA-A&#x0002a;02</italic> did not substantially change after conditioning for each <italic>DRB1</italic> allele separately (data not shown). In addition, <italic>Cw&#x0002a;05</italic> showed very similar results after conditioning for each <italic>DRB1</italic> allele with the notable exception of <italic>DRB1&#x0002a;03</italic>: a protective effect with borderline significance was evidenced for <italic>HLA-Cw&#x0002a;05</italic> when considering only <italic>DRB1&#x0002a;03-</italic>negative individuals (OR=0.58, 95&#x00025; CI=0.36&#x02013;0.92; <italic>P</italic>=0.02). When the same procedure was applied to the different <italic>A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic> combinations, there was no substantial difference after conditioning for each <italic>DRB1</italic> allele separately, again with the exception of <italic>DRB1&#x0002a;03</italic> (<xref rid="tbl5" ref-type="table">Table 5</xref>). Interestingly, the <italic>A&#x0002a;02</italic> negative, <italic>Cw&#x0002a;05</italic> positive combination was significantly increased among <italic>DRB1&#x0002a;03-</italic>positive individuals (OR=3.89), whereas it was not significantly associated with MS among <italic>DRB1&#x0002a;03-</italic>negative individuals (OR=0.96). The <italic>A&#x0002a;02</italic> positive, <italic>Cw&#x0002a;05</italic> positive combination remained significantly protective both in <italic>DRB1&#x0002a;03</italic> positive (OR=0.28) and negative (OR=0.39) individuals. Thus, the presence of <italic>Cw&#x0002a;05</italic> was significantly protective in combination with <italic>A&#x0002a;02</italic>, independently of <italic>DRB1</italic>, whereas in the absence of <italic>A&#x0002a;02</italic>, it behaved as a risk marker in combination with <italic>DRB1&#x0002a;03</italic> (<xref rid="tbl5" ref-type="table">Table 5</xref>).</p></sec></sec><sec><title>Discussion</title><p>This work stems from previous studies undertaken by our group and others, each reporting an MS association with distinct HLA-class I markers, namely <italic>HLA-A&#x0002a;02</italic>,<sup><xref ref-type="other" rid="bib9">9</xref>, <xref ref-type="other" rid="bib13">13</xref></sup><italic>HLA-Cw&#x0002a;05</italic><sup><xref ref-type="other" rid="bib11">11</xref></sup> and <italic>MOG-142L</italic>.<sup><xref ref-type="other" rid="bib12">12</xref></sup> We here analyze the relationship among these three markers for MS susceptibility.</p><p>We confirmed a strong protective effect of <italic>HLA-A&#x0002a;02</italic>, which was independent of <italic>DRB1&#x0002a;15</italic> as well as of any other <italic>DRB1</italic> allele. This association has now been detected, with similar ORs, in three populations with a different genetic background, respectively, from Italy (this paper), Sweden<sup><xref ref-type="other" rid="bib9">9</xref></sup> and Tasmania<sup><xref ref-type="other" rid="bib13">13</xref></sup> based on a total of over 2600 MS patients and 2700 controls. These data concur to demonstrate a role in MS of this allele (or of a variation in LD with it). Conversely, Chao <italic>et al.</italic><sup><xref ref-type="other" rid="bib7">7</xref></sup> failed to observe a transmission distortion of the <italic>HLA-A&#x0002a;02</italic> allele in a large family sample from Canada and no SNPs in the <italic>HLA-A</italic> region showed association with MS independently of <italic>HLA-</italic>class II loci in Canadian and Finnish families.<sup><xref ref-type="other" rid="bib8">8</xref></sup> As both these studies were based on an intrafamilial association method, an obvious explanation of the discrepancy could be a stratification problem related to the case&#x02013;control approach used in the present as well as the other two studies.<sup><xref ref-type="other" rid="bib9">9</xref>, <xref ref-type="other" rid="bib13">13</xref></sup> However, as a significant <italic>HLA-A&#x0002a;02</italic> association was seen in independent studies and in three different populations, this simple explanation seems unlikely and further studies are needed to address this point.</p><p>The <italic>HLA-A&#x0002a;02</italic> protection remained similar after accounting for the other two analyzed class I markers. Conversely, the protective effect of <italic>MOG-142L</italic> was secondary to its high linkage disequilibrium with <italic>HLA-A&#x0002a;02</italic>. This excluded a direct role of the missense <italic>V142L</italic> variation in the <italic>MOG</italic> gene, a previously suggested strong MS susceptibility candidate (reviewed in D'Alfonso <italic>et al.</italic><sup><xref ref-type="other" rid="bib12">12</xref></sup>).</p><p>In this study, <italic>Cw&#x0002a;05</italic> was not associated with MS either in the whole sample or in <italic>DRB1&#x0002a;15-</italic>negative individuals. However, when stratifying the results separately for all <italic>DRB1</italic> alleles, <italic>Cw&#x0002a;05</italic> conferred a significant protection for MS in the subgroup of individuals negative for <italic>DRB1&#x0002a;03</italic>. This is partially in line with the data reported by Yeo <italic>et al.</italic><sup><xref ref-type="other" rid="bib11">11</xref></sup> who observed a protective effect of <italic>Cw&#x0002a;05</italic> in the whole sample as well as in individuals negative for <italic>DRB1&#x0002a;03</italic> and other MS-associated <italic>DRB1</italic> alleles (<italic>DRB1&#x0002a;15</italic>, <italic>DRB1&#x0002a;0103</italic>). Conversely, in <italic>DRB1&#x0002a;03-</italic>positive individuals, and in the absence of <italic>A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic> was a risk marker and conferred a risk similar to <italic>DRB1&#x0002a;15</italic> (OR=3.89, <italic>P</italic>=0.0006). Moreover, <italic>Cw&#x0002a;05</italic> significantly enhanced the protection effect of <italic>HLA-A&#x0002a;02</italic>: the OR conferred by <italic>A&#x0002a;02</italic> among <italic>Cw&#x0002a;05-</italic>positive individuals (OR=0.22, 95&#x00025; CI=0.13&#x02013;0.38) was about 1/3 smaller than among <italic>Cw&#x0002a;05-</italic>negative individuals (OR=0.69, 95&#x00025; CI=0.58&#x02013;0.83). Thus, although <italic>Cw&#x0002a;05</italic> itself was not significantly associated to MS, it behaved as a modifier of the <italic>HLA-A&#x0002a;02-</italic>mediated protection. The protective effect of the <italic>Cw&#x0002a;05-A&#x0002a;02</italic> combination was independent of the presence of <italic>DRB1&#x0002a;03</italic> (<xref rid="tbl5" ref-type="table">Table 5</xref>).</p><p>These data suggest that the association of <italic>Cw&#x0002a;05</italic> with MS varies according to its haplotypic context. <italic>Cw&#x0002a;05</italic> is a marker of three ancestral or conserved extended HLA haplotypes,<sup><xref ref-type="other" rid="bib14">14</xref>, <xref ref-type="other" rid="bib15">15</xref>, <xref ref-type="other" rid="bib16">16</xref></sup> one of which carries <italic>DRB1&#x0002a;03</italic> and is negative for <italic>A&#x0002a;02</italic>, namely 18.2 [<italic>A&#x0002a;30</italic>, <italic>Cw&#x0002a;05</italic>, <italic>B&#x0002a;18</italic>, <italic>DRB1&#x0002a;03</italic>], and the other two carry <italic>A&#x0002a;02</italic>, but not <italic>DRB1&#x0002a;03</italic>, namely 44.1 [<italic>A&#x0002a;0201</italic>, <italic>Cw&#x0002a;0501</italic>, <italic>B&#x0002a;4402</italic>, <italic>DRB1&#x0002a;0401</italic>] and 18.3 [<italic>A&#x0002a;0201</italic>, <italic>Cw&#x0002a;0501</italic>, <italic>B&#x0002a;1801</italic>, <italic>DRB1&#x0002a;1102</italic>].</p><p>The 18.2 HLA-extended haplotype is typical of the Sardinian population and, to a lesser extent, of other Mediterranean populations. Conversely, in the populations of northern European origin, this DR3 haplotype is very rare and the majority of <italic>DRB1&#x0002a;03-</italic>positive individuals carry the 8.1 [<italic>A1, Cw&#x0002a;07, B&#x0002a;08, DRB1&#x0002a;03</italic>] extended haplotype. The positive association of the <italic>A&#x0002a;02</italic>&#x02212;, <italic>Cw&#x0002a;05</italic>&#x0002b;, <italic>DRB1&#x0002a;03&#x0002b;</italic> combination observed in this study may reflect the effect of the 18.2 haplotype. It is tempting to speculate that the strong positive association of MS with <italic>DRB1&#x0002a;03</italic> observed in Sardinia is related to the 18.2 haplotype and not only to <italic>DRB1&#x0002a;03</italic> itself.</p><p>As stated above, the <italic>A&#x0002a;02-Cw&#x0002a;05</italic> combination is carried by two HLA ancestral haplotypes (44.1 and 18.3). However, as the individuals included in this study were not typed for HLA-B and other HLA markers, from our data it is not possible to conclude whether the enhanced MS-protective effect of the <italic>A&#x0002a;02-Cw&#x0002a;05</italic> combination is due to an haplotype effect (that is the presence of a primarily associated protective factor carried by the extended haplotype marked by <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic>) or to a direct interactive role of the two markers.</p><p>The evidence in favor of an haplotype effect is as follows: (i) <italic>Cw&#x0002a;05</italic> was not associated with MS in the absence of <italic>A&#x0002a;02</italic>. Actually, <italic>Cw&#x0002a;05</italic> behaved as a protective factor among <italic>A&#x0002a;02-</italic>positive individuals (OR=0.50, 95&#x00025; CI 0.33&#x02013;0.74) and as a risk factor among <italic>A&#x0002a;02-</italic>negative individuals (OR=1.53, 95&#x00025; CI 1.04&#x02013;2.24). (ii) In family trios, out of 10 haplotypes that carried both <italic>A&#x0002a;02</italic> and <italic>Cw&#x0002a;05</italic>, none were transmitted to the MS patients (T:NT=0:10; <italic>P</italic>=0.002). The only <italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b; MS patient present in this panel inherited the two alleles in trans. (iii) Each of the <italic>A&#x0002a;02</italic>, <italic>B&#x0002a;44</italic> and <italic>Cw&#x0002a;05</italic> alleles (characterizing the 44.1 ancestral haplotype) was significantly decreased in the study of Yeo <italic>et al.</italic><sup><xref ref-type="other" rid="bib11">11</xref></sup> However, the association with the <italic>A&#x0002a;02-B&#x0002a;44-Cw&#x0002a;05</italic> haplotypic combination was not investigated by the authors.</p><p>On the other hand, evidence reported in this study and from work undertaken using an experimental animal model<sup><xref ref-type="other" rid="bib17">17</xref></sup> points to a direct role of <italic>A&#x0002a;02</italic>. In our study, A<sup>&#x0002a;</sup>02 was also significantly protective in the absence of Cw<sup>&#x0002a;</sup>05 (OR=0.73, <italic>P</italic>&#x0003c;10<sup>&#x02212;4</sup>). Thus, an effect of A<sup>&#x0002a;</sup>02 alone cannot be excluded. Moreover, Friese <italic>et al.</italic><sup><xref ref-type="other" rid="bib17">17</xref></sup> recently reported that the MS-like disease developed by double transgenic mice expressing both a human HLA-class I allele (A<sup>&#x0002a;</sup>03) and a human myelin-specific autoreactive T-cell receptor is completely prevented by further adding an <italic>HLA-A&#x0002a;0201</italic> transgene. Thus, A<sup>&#x0002a;</sup>02, which protects against MS in human populations, also prevents an MS-like disease in transgenic humanized mice. This protection resulted from thymic deletion of autoreactive T cells, which greatly reduced their number in the periphery.<sup><xref ref-type="other" rid="bib17">17</xref></sup></p><p>Both <italic>HLA-A</italic> and <italic>-C</italic> genes are interesting candidates for a direct role in MS pathogenesis, as their encoded molecules present antigenic peptides and interact with NK receptors.<sup><xref ref-type="other" rid="bib18">18</xref>, <xref ref-type="other" rid="bib19">19</xref></sup> However, several other genes in this region might be primarily associated with MS. The 1.3&#x02009;Mb interval within HLA-A and -C genes contains 46 genes (24&#x00025; of which encoding molecules involved in immune functions) and about 4000 SNPs, according to the recently reported sequence of eight HLA ancestral haplotypes<sup><xref ref-type="other" rid="bib20">20</xref></sup> and HapMap data (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.hapmap.org/">http://www.hapmap.org/</ext-link>). A genome-wide association study<sup><xref ref-type="other" rid="bib21">21</xref></sup> in about 1000 US MS patients and 1000 matched controls identified several MS-associated SNPs in the HLA-class I region after conditioning for HLA-DRB1<sup>&#x0002a;</sup>15. Among these, the top signals were localized around members of the tripartite motif (TRIM) gene family, mapping about 200&#x02009;kb centromeric to HLA-A. Although their function is unknown, the presence of a RING domain suggests DNA-binding activity.<sup><xref ref-type="other" rid="bib21">21</xref></sup></p><p>In conclusion, this study provides additional supportive evidence indicating that the HLA-class I region does indeed exert an additional influence on the risk of MS, analogous to that reported for other autoimmune diseases.<sup><xref ref-type="other" rid="bib22">22</xref>, <xref ref-type="other" rid="bib23">23</xref>, <xref ref-type="other" rid="bib24">24</xref></sup> Moreover, it identifies haplospecific markers conferring a high MS protection. Notably, although in general DRB1<sup>&#x0002a;</sup>15-negative individuals have an about threefold lower MS risk relative to DRB1<sup>&#x0002a;</sup>15-positive individuals, their risk was significantly decreased (about eightfold) if they also carried A<sup>&#x0002a;</sup>02 and Cw<sup>&#x0002a;</sup>05 (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The highly protective A<sup>&#x0002a;</sup>02-Cw<sup>&#x0002a;</sup>05 combination is rare (0.078 phenotypic frequency in our controls, 0.025 haplotype frequency in our family trios) and, therefore, unless it tags a primary factor with higher frequency, it confers a modest modification of the HLA attributable MS risk in the population. In any case, the identification of the mechanism mediating the protective effect might throw new light on MS pathogenesis.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Subjects</title><p>A total of 1273 Italian MS patients (female:male ratio 2:1) diagnosed according to McDonald <italic>et al.</italic>,<sup><xref ref-type="other" rid="bib25">25</xref></sup> were genotyped for the three HLA-class I markers considered in this study and for DRB1<sup>&#x0002a;</sup>15. For 201 of these, a DNA sample of the parents was also available (family trios). The mean age of the MS patients at disease onset was 31&#x000b1;10.16 years, the mean age at time of analysis was 40&#x000b1;15.52 years and the mean disease duration was 12&#x000b1;9.31 years. Eighty-four percent of the patients were affected by the relapsing remitting, 7&#x00025; by the secondary progressive and 9&#x00025; by the primary progressive form of the disease, defined according to Lublin and Reingold.<sup><xref ref-type="other" rid="bib26">26</xref></sup> MS patients with Sardinian ancestors were excluded to avoid the introduction of confounding sources of heterogeneity. Enrolment of the MS patients followed their informed consent. The study was approved by the Ethical Committees of the collaborating clinical centers.</p><p>Controls included 1075 Italian individuals (medical students, university and hospital staff, blood donors; female:male ratio 1:1.1) matched for age and regional origin with the MS patients and also typed for all considered markers.</p><p>MS patients (82&#x00025;) and controls (30&#x00025;) in part overlap with those included in a previous paper<sup><xref ref-type="other" rid="bib12">12</xref></sup> and were selected for inclusion on the basis of the availability of DNA and of HLA genotypes.</p></sec><sec><title>MOG-V142L typing</title><p>The newly included samples were typed using a pre-designed TaqMan SNP Genotyping Assay (probe code: C__25474376_10). Reactions were performed according to the manufacturer's protocol using 25&#x02009;ng of DNA. The PCR reaction was set up on a 7000 Applied Biosystems instrument. Genotypes were detected using the 7000 System Software (Applied Biosystems, Foster City, CA, USA).</p><p>A sub-sample of 60 individuals were typed both with this method and with the method used in the previous paper.<sup><xref ref-type="other" rid="bib12">12</xref></sup> The results were consistent for all tested samples.</p></sec><sec><title>HLA-A<sup>&#x0002a;</sup>02 typing</title><p><italic>HLA-A</italic> exon 2 was amplified using a specific couple of primers (Forward: 5&#x02032;-CGACGCCGCGAGCCAGA<bold>R</bold>GAT-3&#x02032;, Reverse: 5&#x02032;-GGCCCGTCCGTGGGGGATGA-3&#x02032;). The PCR product (213&#x02009;bp) was digested using the restriction enzyme Kpn2 I. This enzyme recognizes and cuts the rs3173427-T sequence that is specific of <italic>HLA-A&#x0002a;02</italic>. By this approach, it was possible to distinguish <italic>HLA-A&#x0002a;02</italic> homozygotes (displaying two fragments of 159 and 54&#x02009;bp) from heterozygotes (displaying three fragments of 159, 54 and 213&#x02009;bp). The digestion was performed at 55&#x02009;&#x000b0;C for 4&#x02009;h, and then the enzyme was inactivated at 80&#x02009;&#x000b0;C for 20&#x02009;min.</p><p><italic>HLA-A&#x0002a;02-</italic>positive individuals of family trios were also analyzed by sequencing exon 2 and exon 3 to define <italic>HLA-A&#x0002a;02</italic> alleles at a higher resolution. Exon 2 and 3 were amplified together in the same fragment (Forward: 5&#x02032;-CGACGCCGCGAGCCAGA<bold>R</bold>GAT-3&#x02032;, Reverse: 5&#x02032;-AACGGGAAGGAGACGCTGC-3&#x02032;). The reaction mix was performed using 0.02&#x02009;U&#x02009;&#x003bc;l<sup>&#x02013;1</sup> TaqAB, 0.2&#x02009;pmol&#x02009;&#x003bc;l<sup>&#x02013;1</sup> of every primers, 1.75&#x02009;m<sc>M</sc> MgCl<sub>2</sub> and glycerol to 7.4&#x00025;. PCR was made at 60&#x02009;&#x000b0;C annealing temperature for 35 cycles. PCR products were sequenced using nested primers: 5&#x02032;-GGCCCGTCCGTGGGGGATGA-3&#x02032; for exon 2 and 5&#x02032;-TCAGTTTAGGCCAAAAATCC-3&#x02032; for exon 3. Sequences were analyzed with the automatic sequencer Applied Biosystems (ABI) 3100.</p></sec><sec><title>HLA-Cw<sup>&#x0002a;</sup>05 allele-specific PCR</title><p>All the samples were typed for <italic>HLA-Cw&#x0002a;05</italic> by an allele-specific PCR after the conditions of the 12th International Histocompatibility Workshop.<sup><xref ref-type="other" rid="bib27">27</xref></sup> In detail, specific primers pairs were used to amplify in the same tube HLA-Cw<sup>&#x0002a;</sup>05 (Forward: 5&#x02032;-CCGAGTGAACCTGCGGAAA-3&#x02032;, Reverse: 5&#x02032;-CGCGCGCTGCAGCGTCTT-3&#x02032;) and a 796&#x02009;bp internal control fragment (Forward: 5&#x02032;-TGCCAAGTGGAGCACCCAA-3&#x02032;, Reverse: 5&#x02032;-GCATCTTGCTCTGTGCAGAT-3&#x02032;). The reaction mix contained 0.02 U&#x02009;&#x003bc;l<sup>&#x02013;1</sup> TaqAB (AB Analitica), 1&#x02009;pmol&#x02009;&#x003bc;l<sup>&#x02013;1</sup> of <italic>HLA-Cw&#x0002a;05-</italic>specific primers, 0.33&#x02009;pmol&#x02009;&#x003bc;l<sup>&#x02013;1</sup> of internal control primers and 2&#x02009;m<sc>M</sc> of MgCl<sub>2</sub>. By this approach, it was possible to specifically identify all the samples positive for <italic>HLA-Cw&#x0002a;05</italic>, but not to distinguish between Cw<sup>&#x0002a;</sup>05 homozygotes and heterozygotes.</p></sec><sec><title>DRB1 locus analysis</title><p>For 562 MS cases and 888 controls, a complete low-resolution <italic>DRB1</italic> typing was already available. <italic>DRB1</italic> alleles were typed by the DR low-resolution PCR-SSP (Sequence Specific Primer amplification) kit (Dynal or BAG, Formedic, Milan, Italy).</p><p>The remaining MS patients and controls were typed only for <italic>DRB1&#x0002a;15</italic> by an allele-specific PCR (Forward primer: 5&#x02032;-CCTGTGGCAGCCTAAGAGG-3&#x02032;, Reverse primer: 5&#x02032;-CCGCGCCTGCTCCAGGAT-3&#x02032;) with an internal control fragment (Forward: 5&#x02032;-TGTTCTGTATTTGTGTTGTCTGATG-3&#x02032;, Reverse: 5&#x02032;-GTGCTCAGAGAGGCAAGGTT-3&#x02032;). The reaction mix contained 0.02&#x02009;U&#x02009;&#x003bc;l<sup>&#x02013;1</sup> TaqAB (Applied Biosystems), 0.5&#x02009;pmol&#x02009;&#x003bc;l<sup>&#x02013;1</sup> DRB1<sup>&#x0002a;</sup>15-specific primers, 0.25&#x02009;pmol&#x02009;&#x003bc;l<sup>&#x02013;1</sup> of internal control primers and 1.5&#x02009;m<sc>M</sc> of MgCl<sub>2</sub>. By this approach, it was possible to specifically identify all the samples positive for DRB1<sup>&#x0002a;</sup>15, but not to distinguish between DRB1<sup>&#x0002a;</sup>15 homozygotes and heterozygotes.</p></sec><sec><title>Quality control of allele-specific HLA typing</title><p>The genotype methods used to type A<sup>&#x0002a;</sup>02, Cw<sup>&#x0002a;</sup>05 and DRB1<sup>&#x0002a;</sup>15 alleles were validated by typing 51 HLA homozygous typing cell lines from the reference panel of the 12th International Histocompatibility Workshop<sup><xref ref-type="other" rid="bib27">27</xref></sup> and 55 individuals previously typed with a commercial kit.</p></sec><sec><title>Statistical analysis</title><p>Unconditional logistical regression was carried out to determine the effect of the considered markers on MS susceptibility. The association of each polymorphism with the disease was measured by the OR and its 95&#x00025; CI. Reported <italic>P</italic>-values were not corrected for the number of comparisons.</p><p>The potential confounding variables were assessed individually by comparing the log-likelihood ratios derived from a model with and without the variable. This analysis was set up using multivariate models using the four considered markers. All analyses were adjusted for sex. The different models were compared by the likelihood ratio test.</p><p>The interaction (modification) effect was assessed by comparing ORs across levels of potential modifying variables. Inclusion of appropriate interaction terms in the logistic regression model was used to assess the statistical significance of the interactions. For each marker, the potential effect modification by sex variable was also tested.</p><p>The main-effects test of the COCAPHASE program, part of the UNPHASED suite,<sup><xref ref-type="other" rid="bib28">28</xref></sup> was used for conditional analysis on DRB1. This program provides association tests conditioning on additional loci, which may already be associated and in linkage disequilibrium with the test loci. The EM algorithm is used to obtain maximium-likelihood estimates of haplotypes.</p><p>LD were calculated from phenotypes according to Mattiuz <italic>et al.</italic><sup><xref ref-type="other" rid="bib29">29</xref></sup> Estimates for Global D' and Cramer's V (measures of LD between multiallelic loci) were calculated using the COCAPHASE program.<sup><xref ref-type="other" rid="bib28">28</xref></sup></p></sec></sec><sec><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec></body><back><ack><p>This work was supported by the Italian Foundation for Multiple Sclerosis (FISM grants 2001/R/44, 2002/R/40 and 2005/R/10, 2008/R/11); CARIPLO Foundation, Regione Piemonte Ricerca Sanitaria Finalizzata (grants 2003, 2004, 2007, 2008), Regione Piemonte CIPE 2004, Ministry of Health (ricerca finalizzata grant 2004.80), Eastern Piedmont University (grants to SD and PMR). Compagnia di San Paolo (Turin), Fondazione CRT (Turin). DG and ES were supported by Fondazione Monzino, Ospedale Maggiore Policlinico and Ing. Cesare Cusan. NB was supported by a fellowship from FISM (2003/B/2). LB is a &#x02018;Biotechnology for Health' PhD student supported by a PhD Lagrange Fellowship. We are grateful to the patients and their parents and also to Professor Corrado Magnani for helpful discussion and to Dr Roberto Tosi for critical suggestions.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Coles</surname><given-names>A</given-names></name></person-group><article-title>Multiple sclerosis</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1502</fpage><lpage>1517</lpage><!--PubMed citation query: 'Lancet||372|1502||bib1|'--><pub-id pub-id-type="pmid">18970977</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebers</surname><given-names>GC</given-names></name></person-group><article-title>Environmental factors and multiple sclerosis</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><fpage>268</fpage><lpage>277</lpage><!--PubMed citation query: 'Lancet Neurol||7|268||bib2|'--><pub-id pub-id-type="pmid">18275928</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ballerini</surname><given-names>C</given-names></name><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Rombol&#x000e0;</surname><given-names>G</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Massacesi</surname><given-names>L</given-names></name><name><surname>Ferrante</surname><given-names>P</given-names></name><etal/></person-group><article-title>HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe</article-title><source>J Neuroimmunol</source><year>2004</year><volume>150</volume><fpage>178</fpage><lpage>185</lpage><!--PubMed citation query: 'J Neuroimmunol||150|178||bib3|'--><pub-id pub-id-type="pmid">15081263</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fogdell</surname><given-names>A</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><name><surname>Sachs</surname><given-names>C</given-names></name><name><surname>Olerup</surname><given-names>O</given-names></name></person-group><article-title>The multiple sclerosis-and narcolepsy-associated HLA class II Haplotype incluse DRB5<sup>&#x0002a;</sup>0101 allele</article-title><source>Tissue Antigens</source><year>1995</year><volume>46</volume><fpage>333</fpage><lpage>336</lpage><!--PubMed citation query: 'Tissue Antigens||46|333||bib4|'--><pub-id pub-id-type="pmid">8560455</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olerup</surname><given-names>O</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name></person-group><article-title>HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation</article-title><source>Tissue Antigens</source><year>1991</year><volume>38</volume><fpage>1</fpage><lpage>15</lpage><!--PubMed citation query: 'Tissue Antigens||38|1||bib5|'--><pub-id pub-id-type="pmid">1926129</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barcellos</surname><given-names>LF</given-names></name><name><surname>Sawcer</surname><given-names>S</given-names></name><name><surname>Ramsay</surname><given-names>PP</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Thomson</surname><given-names>G</given-names></name><name><surname>Briggs</surname><given-names>F</given-names></name><etal/></person-group><article-title>Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume><fpage>2813</fpage><lpage>2824</lpage><!--PubMed citation query: 'Hum Mol Genet||15|2813||bib6|'--><pub-id pub-id-type="pmid">16905561</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>MJ</given-names></name><name><surname>Barnardo</surname><given-names>MC</given-names></name><name><surname>Lui</surname><given-names>GZ</given-names></name><name><surname>Lincoln</surname><given-names>MR</given-names></name><name><surname>Ramagopalan</surname><given-names>SV</given-names></name><name><surname>Herrera</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium</article-title><source>Hum Mol Genet</source><year>2007</year><volume>16</volume><fpage>1951</fpage><lpage>1958</lpage><!--PubMed citation query: 'Hum Mol Genet||16|1951||bib7|'--><pub-id pub-id-type="pmid">17584771</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lincoln</surname><given-names>MR</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Cader</surname><given-names>MZ</given-names></name><name><surname>Saarela</surname><given-names>J</given-names></name><name><surname>Dyment</surname><given-names>DA</given-names></name><name><surname>Tiislar</surname><given-names>M</given-names></name><etal/></person-group><article-title>A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>1108</fpage><lpage>1112</lpage><!--PubMed citation query: 'Nat Genet||37|1108||bib8|'--><pub-id pub-id-type="pmid">16186814</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brynedal</surname><given-names>B</given-names></name><name><surname>Duvefelt</surname><given-names>K</given-names></name><name><surname>Jonasdottir</surname><given-names>G</given-names></name><name><surname>Roos</surname><given-names>IM</given-names></name><name><surname>Akesson</surname><given-names>E</given-names></name><name><surname>Palmgren</surname><given-names>J</given-names></name><etal/></person-group><article-title>HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis</article-title><source>PLoS One</source><year>2007</year><volume>7</volume><fpage>e664</fpage><!--PubMed citation query: 'PLoS One||7|e664||bib9|'--></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fogdell-Hahn</surname><given-names>A</given-names></name><name><surname>Ligers</surname><given-names>A</given-names></name><name><surname>Gronning</surname><given-names>M</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><name><surname>Olerup</surname><given-names>O</given-names></name></person-group><article-title>Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease</article-title><source>Tissue Antigens</source><year>2000</year><volume>55</volume><fpage>140</fpage><lpage>148</lpage><!--PubMed citation query: 'Tissue Antigens||55|140||bib10|'--><pub-id pub-id-type="pmid">10746785</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>TW</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Gregory</surname><given-names>SG</given-names></name><name><surname>Barcellos</surname><given-names>LF</given-names></name><name><surname>Walton</surname><given-names>A</given-names></name><name><surname>Goris</surname><given-names>A</given-names></name><etal/></person-group><article-title>A second major histocompatibility complex susceptibility locus for multiple sclerosis</article-title><source>Ann Neurol</source><year>2007</year><volume>61</volume><fpage>228</fpage><lpage>236</lpage><!--PubMed citation query: 'Ann Neurol||61|228||bib11|'--><pub-id pub-id-type="pmid">17252545</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Alfonso</surname><given-names>S</given-names></name><name><surname>Bolognesi</surname><given-names>E</given-names></name><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Barizzone</surname><given-names>N</given-names></name><name><surname>Bocca</surname><given-names>S</given-names></name><name><surname>Ferrante</surname><given-names>D</given-names></name><etal/></person-group><article-title>A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy</article-title><source>Genes Immun</source><year>2008</year><volume>9</volume><fpage>7</fpage><lpage>15</lpage><!--PubMed citation query: 'Genes Immun||9|7||bib12|'--><pub-id pub-id-type="pmid">17928868</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burfoot</surname><given-names>RK</given-names></name><name><surname>Jensen</surname><given-names>CJ</given-names></name><name><surname>Field</surname><given-names>J</given-names></name><name><surname>Stankovich</surname><given-names>J</given-names></name><name><surname>Varney</surname><given-names>MD</given-names></name><name><surname>Johnson</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians</article-title><source>Tissue Antigens</source><year>2008</year><volume>71</volume><fpage>42</fpage><lpage>50</lpage><!--PubMed citation query: 'Tissue Antigens||71|42||bib13|'--><pub-id pub-id-type="pmid">17971048</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cattley</surname><given-names>SK</given-names></name><name><surname>Williamson</surname><given-names>JF</given-names></name><name><surname>Tay</surname><given-names>GK</given-names></name><name><surname>Martinez</surname><given-names>OP</given-names></name><name><surname>Gaudieri</surname><given-names>S</given-names></name><name><surname>Dawkins</surname><given-names>RL</given-names></name></person-group><article-title>Further characterization of MHC haplotypes demonstrates conservation telomeric of HLA-A: update of the 4AOH and 10IHW cell panels</article-title><source>Eur J Immunogenet</source><year>2000</year><volume>27</volume><fpage>397</fpage><lpage>426</lpage><!--PubMed citation query: 'Eur J Immunogenet||27|397||bib14|'--><pub-id pub-id-type="pmid">11029610</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alper</surname><given-names>CA</given-names></name><name><surname>Larsen</surname><given-names>CE</given-names></name><name><surname>Dubey</surname><given-names>DP</given-names></name><name><surname>Awdeh</surname><given-names>ZL</given-names></name><name><surname>Fici</surname><given-names>DA</given-names></name><name><surname>Yunis</surname><given-names>EJ</given-names></name></person-group><article-title>The haplotype structure of the human major histocompatibility complex</article-title><source>Hum Immunol</source><year>2006</year><volume>67</volume><fpage>73</fpage><lpage>84</lpage><!--PubMed citation query: 'Hum Immunol||67|73||bib15|'--><pub-id pub-id-type="pmid">16698428</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorak</surname><given-names>MT</given-names></name><name><surname>Shao</surname><given-names>W</given-names></name><name><surname>Machulla</surname><given-names>HK</given-names></name><name><surname>Lobashevsky</surname><given-names>ES</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Conserved extended haplotypes of the major histocompatibility complex: further characterization</article-title><source>Genes Immun</source><year>2006</year><volume>7</volume><fpage>450</fpage><lpage>467</lpage><!--PubMed citation query: 'Genes Immun||7|450||bib16|'--><pub-id pub-id-type="pmid">16791278</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friese</surname><given-names>MA</given-names></name><name><surname>Jakobsen</surname><given-names>KB</given-names></name><name><surname>Friis</surname><given-names>L</given-names></name><name><surname>Etzensperger</surname><given-names>R</given-names></name><name><surname>Craner</surname><given-names>MJ</given-names></name><name><surname>McMahon</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Opposing effects of HLA class I molecules in tuning autoreactive CD8&#x0002b; T cells in multiple sclerosis</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>1227</fpage><lpage>1235</lpage><!--PubMed citation query: 'Nat Med||14|1227||bib17|'--><pub-id pub-id-type="pmid">18953350</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moretta</surname><given-names>L</given-names></name><name><surname>Moretta</surname><given-names>A</given-names></name></person-group><article-title>Killer immunoglobulin-like receptors</article-title><source>Curr Opin Immunol</source><year>2004</year><volume>16</volume><fpage>626</fpage><lpage>633</lpage><!--PubMed citation query: 'Curr Opin Immunol||16|626||bib18|'--><pub-id pub-id-type="pmid">15342010</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thananchai</surname><given-names>H</given-names></name><name><surname>Gillespie</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>MP</given-names></name><name><surname>Bashirova</surname><given-names>A</given-names></name><name><surname>Yawata</surname><given-names>N</given-names></name><name><surname>Yawata</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>33</fpage><lpage>37</lpage><!--PubMed citation query: 'J Immunol||178|33||bib19|'--><pub-id pub-id-type="pmid">17182537</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>R</given-names></name><name><surname>Gibson</surname><given-names>R</given-names></name><name><surname>Coggill</surname><given-names>P</given-names></name><name><surname>Miretti</surname><given-names>M</given-names></name><name><surname>Allcock</surname><given-names>RJ</given-names></name><name><surname>Almeida</surname><given-names>J</given-names></name><etal/></person-group><article-title>Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project</article-title><source>Immunogenetics</source><year>2008</year><volume>60</volume><fpage>1</fpage><lpage>18</lpage><!--PubMed citation query: 'Immunogenetics||60|1||bib20|'--><pub-id pub-id-type="pmid">18193213</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gibson</surname><given-names>RA</given-names></name><name><surname>Galwey</surname><given-names>N</given-names></name><name><surname>Naegelin</surname><given-names>Y</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><etal/></person-group><article-title>Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis</article-title><source>Hum Mol Genet</source><year>2009</year><volume>18</volume><fpage>767</fpage><lpage>778</lpage><!--PubMed citation query: 'Hum Mol Genet||18|767||bib21|'--><pub-id pub-id-type="pmid">19010793</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howson</surname><given-names>JM</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Clayton</surname><given-names>D</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><collab>Diabetes Genetics Consortium</collab></person-group><article-title>Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A</article-title><source>Diabetes Obes Metab</source><year>2009</year><volume>11</volume><supplement>Suppl 1</supplement><fpage>31</fpage><lpage>45</lpage><!--PubMed citation query: 'Diabetes Obes Metab||11|31||bib22|'--><pub-id pub-id-type="pmid">19143813</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eike</surname><given-names>MC</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Humphreys</surname><given-names>K</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name><name><surname>Lie</surname><given-names>BA</given-names></name></person-group><article-title>Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B</article-title><source>Genes Immun</source><year>2009</year><volume>10</volume><fpage>56</fpage><lpage>67</lpage><!--PubMed citation query: 'Genes Immun||10|56||bib23|'--><pub-id pub-id-type="pmid">18830248</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolognesi</surname><given-names>E</given-names></name><name><surname>Karell</surname><given-names>K</given-names></name><name><surname>Percopo</surname><given-names>S</given-names></name><name><surname>Coto</surname><given-names>I</given-names></name><name><surname>Greco</surname><given-names>L</given-names></name><name><surname>Mantovani</surname><given-names>V</given-names></name><etal/></person-group><article-title>Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease</article-title><source>Tissue Antigens</source><year>2003</year><volume>61</volume><fpage>308</fpage><lpage>316</lpage><!--PubMed citation query: 'Tissue Antigens||61|308||bib24|'--><pub-id pub-id-type="pmid">12753669</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>WI</given-names></name><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Edan</surname><given-names>G</given-names></name><name><surname>Goodkin</surname><given-names>D</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name><name><surname>Lublin</surname><given-names>FD</given-names></name><etal/></person-group><article-title>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</article-title><source>Ann Neurol</source><year>2001</year><volume>50</volume><fpage>121</fpage><lpage>127</lpage><!--PubMed citation query: 'Ann Neurol||50|121||bib25|'--><pub-id pub-id-type="pmid">11456302</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lublin</surname><given-names>FD</given-names></name><name><surname>Reingold</surname><given-names>SC</given-names></name></person-group><article-title>Defining the clinical course of multiple sclerosis: results of an international survey</article-title><source>Neurology</source><year>1996</year><volume>48</volume><fpage>907</fpage><lpage>911</lpage><!--PubMed citation query: 'Neurology||48|907||bib26|'--></citation></ref><ref id="bib27"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Tonks</surname><given-names>S</given-names></name><name><surname>Marsh</surname><given-names>SGE</given-names></name><name><surname>Bunce</surname><given-names>M</given-names></name><name><surname>Moses</surname><given-names>JH</given-names></name><name><surname>Krausa</surname><given-names>P</given-names></name><name><surname>Sadler</surname><given-names>AM</given-names></name><etal/></person-group><article-title>HLA class I DNA typing study</article-title><source>Genetic Diversity of HLA: Functional and Medical Implications</source><year>1997</year><publisher-name>EDK: Sevres</publisher-name><fpage>199</fpage><lpage>215</lpage>In: D Charron (ed).</citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudbridge</surname><given-names>F</given-names></name></person-group><article-title>Pedigree disequilibrium tests for multilocus haplotypes</article-title><source>Genet Epidemiol</source><year>2003</year><volume>25</volume><fpage>115</fpage><lpage>121</lpage><!--PubMed citation query: 'Genet Epidemiol||25|115||bib28|'--><pub-id pub-id-type="pmid">12916020</pub-id></citation></ref><ref id="bib29"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Mattiuz</surname><given-names>PL</given-names></name><name><surname>Ihde</surname><given-names>D</given-names></name><name><surname>Piazza</surname><given-names>A</given-names></name><name><surname>Ceppellini</surname><given-names>R</given-names></name><name><surname>Bodmer</surname><given-names>WD</given-names></name></person-group><article-title>New approaches to the population genetics and segregation analysis of the HLA system</article-title><source>Histocompatibility Testing</source><year>1970</year><publisher-name>Munksgaard: Copenhagen</publisher-name><fpage>193</fpage><lpage>205</lpage>In: P Terasaki (ed).</citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>ORs for the different combinations of <italic>A&#x0002a;02</italic>, <italic>Cw&#x0002a;05</italic> and <italic>DRB1&#x0002a;15</italic> alleles. The combination carrying the HLA-class I alleles conferring the highest protection (<italic>A&#x0002a;02</italic>&#x0002b;, <italic>Cw&#x0002a;05</italic>&#x0002b;) and without the class II risk allele (<italic>DRB1&#x0002a;15</italic>&#x02212;) was used as a reference (OR=1) for the calculation of ORs. Figures in each bar correspond to the 95&#x00025; CI.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="gene2009101f1"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Frequency of <italic>MOG-142L</italic>, <italic>HLA-A&#x0002a;02</italic> and <italic>HLA-Cw&#x0002a;05-</italic>positive individuals among MS patients and controls</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Marker</italic></th><th align="center" valign="top" charoff="50"><italic>Sample</italic></th><th colspan="2" align="center" valign="top" charoff="50"><italic>Frequencies</italic></th><th align="center" valign="top" charoff="50">P<italic>-value</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>OR (95&#x00025; CI)</italic></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><italic>Cases</italic></th><th align="center" valign="top" charoff="50"><italic>Controls</italic></th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="char" valign="top" char="(" charoff="50">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50"><italic>Total</italic></td><td align="center" valign="top" charoff="50">N=<italic>1273</italic></td><td align="center" valign="top" charoff="50">N<italic>=1075</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>MOG-142L</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.285</td><td align="center" valign="top" charoff="50">0.364</td><td align="center" valign="top" charoff="50">4.93 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="char" valign="top" char="(" charoff="50">0.70 (0.59&#x02013;0.83)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>HLA-A&#x0002a;02</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.331</td><td align="center" valign="top" charoff="50">0.448</td><td align="center" valign="top" charoff="50">5.28 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="char" valign="top" char="(" charoff="50">0.61 (0.51&#x02013;0.72)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>HLA-Cw&#x0002a;05</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.101</td><td align="center" valign="top" charoff="50">0.112</td><td align="center" valign="top" charoff="50">NS</td><td align="char" valign="top" char="(" charoff="50">0.85 (0.65&#x02013;1.10)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50"><italic>DR15 negative</italic></td><td align="center" valign="top" charoff="50">N<italic>=883</italic></td><td align="center" valign="top" charoff="50">N<italic>=935</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>MOG-142L</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.293</td><td align="center" valign="top" charoff="50">0.377</td><td align="center" valign="top" charoff="50">1.42 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="char" valign="top" char="(" charoff="50">0.68 (0.56&#x02013;0.84)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>HLA-A&#x0002a;02</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.334</td><td align="center" valign="top" charoff="50">0.464</td><td align="center" valign="top" charoff="50">1.44 &#x000d7; 10<sup>&#x02212;8</sup></td><td align="char" valign="top" char="(" charoff="50">0.58 (0.48&#x02013;0.70)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>HLA-Cw&#x0002a;05</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.108</td><td align="center" valign="top" charoff="50">0.119</td><td align="center" valign="top" charoff="50">NS</td><td align="char" valign="top" char="(" charoff="50">0.89 (0.66&#x02013;1.21)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><label/><p>Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio; NS, not significant.</p></fn><fn id="t1-fn2"><label/><p>Genotype frequencies (&#x0002b;/&#x0002b;, &#x0002b;/&#x02212;, &#x02212;/&#x02212;) in the total MS patient sample vs total controls were 0.02, 0.26, 0.72 vs 0.04, 0.32, 0.64 for <italic>MOG-142L</italic> and 0.04, 0.29, 0.67 vs 0.07, 0.38, 0.55 for <italic>HLA-A&#x0002a;02.</italic> These frequencies did not deviate from Hardy Weinberg equilibrium either in MS patients or controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Logistic regression analysis of <italic>MOG-142L</italic>, <italic>HLA-A&#x0002a;02</italic>, <italic>HLA-Cw&#x0002a; 05</italic> and <italic>DRB1&#x0002a;15</italic> alleles</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="("/><col align="left"/><col align="left"/><col align="left"/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Markers</italic></th><th colspan="5" align="center" valign="top" char="(" charoff="50"><italic>OR (95&#x00025; CI) adjusted values for:</italic></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="char" valign="top" char="(" charoff="50"><italic>MOG-142L</italic></th><th align="left" valign="top" charoff="50"><italic>HLA-A&#x0002a;02</italic></th><th align="left" valign="top" charoff="50"><italic>HLA-Cw&#x0002a;05</italic></th><th align="left" valign="top" charoff="50"><italic>DRB1&#x0002a;15</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>All markers in the model</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>MOG-142L</italic></td><td align="char" valign="top" char="(" charoff="50"><bold>0.70</bold> (<bold>0.59&#x02013;0.83)</bold></td><td align="left" valign="top" charoff="50">0.87 (0.71&#x02013;1.06) <italic>P</italic>=0.1761</td><td align="left" valign="top" charoff="50">0.70 (0.59&#x02013;0.83) <italic>P</italic>=6.2 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="left" valign="top" charoff="50">0.73 (0.61&#x02013;0.87) <italic>P</italic>=0.0004</td><td align="char" valign="top" char="(" charoff="50">0.90 (0.73&#x02013;1.10)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>HLA-A&#x0002a;02</italic></td><td align="char" valign="top" char="(" charoff="50">0.65 (0.53&#x02013;0.79) <italic>P</italic>=1.0 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="left" valign="top" charoff="50"><bold>0.61</bold> (<bold>0.51&#x02013;0.72)</bold></td><td align="left" valign="top" charoff="50">0.61 (0.52&#x02013;0.72) <italic>P</italic>=8.2 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="left" valign="top" charoff="50">0.63 (0.53&#x02013;0.75) <italic>P</italic>=1.0 &#x000d7; 10<sup>&#x02212;7</sup></td><td align="char" valign="top" char="(" charoff="50">0.66 (0.54&#x02013;0.81)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>HLA-Cw&#x0002a;05</italic></td><td align="char" valign="top" char="(" charoff="50">0.87 (0.67&#x02013;1.13) <italic>P</italic>=0.2970</td><td align="left" valign="top" charoff="50">0.90 (0.69&#x02013;1.17) <italic>P</italic>=0.4167</td><td align="left" valign="top" charoff="50"><bold>0.85</bold> (<bold>0.65&#x02013;1.10)</bold></td><td align="left" valign="top" charoff="50">0.88 (0.67&#x02013;1.14) <italic>P</italic>=0.3348</td><td align="char" valign="top" char="(" charoff="50">0.92 (0.71&#x02013;1.21)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>DRB1&#x0002a;15</italic></td><td align="char" valign="top" char="(" charoff="50">2.90 (2.34&#x02013;3.59) <italic>P</italic>=2.8 &#x000d7; 10<sup>&#x02212;24</sup></td><td align="left" valign="top" charoff="50">2.89 (2.33&#x02013;3.58) <italic>P</italic>=6.3 &#x000d7; 10<sup>&#x02212;24</sup></td><td align="left" valign="top" charoff="50">2.94 (2.37&#x02013;3.64) <italic>P</italic>=4.6 &#x000d7; 10<sup>&#x02212;25</sup></td><td align="left" valign="top" charoff="50"><bold>2.95</bold> (<bold>2.38&#x02013;3.65)</bold></td><td align="char" valign="top" char="(" charoff="50">2.87 (2.32&#x02013;3.56)</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label/><p>Abbreviations: CI, confidence intervals; OR, odds ratio.</p></fn><fn id="t2-fn2"><label/><p>Each marker in row is adjusted for markers in columns. In the last column the model includes all the markers.</p></fn><fn id="t2-fn3"><label/><p>The bolded diagonal values contain the crude values for each marker.</p></fn><fn id="t2-fn4"><label/><p><italic>P</italic>-values are obtained from likelihood ratio test comparing the likelihood of the two-gene additive vs the single marker model considering as single marker the marker used for adjustment.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Linkage disequilibria among the three considered HLA-class I markers and <italic>DRB&#x0002a;15</italic> in the control and in the MS patient population</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="center"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" char="(" charoff="50"><italic>Controls</italic></th><th colspan="4" align="center" valign="top" char="(" charoff="50"><italic>MS patients</italic></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="char" valign="top" char="(" charoff="50"><italic>MOG-142L</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>A&#x0002a;02</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>Cw&#x0002a;05</italic></th><th align="center" valign="top" charoff="50"><italic>DRB1&#x0002a;15</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>MOG-142L</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>A&#x0002a;02</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>Cw&#x0002a;05</italic></th><th align="center" valign="top" charoff="50"><italic>DRB1&#x0002a;15</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>MOG-142L</italic></td><td align="char" valign="top" char="(" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>A&#x0002a;02</italic></td><td align="char" valign="top" char="(" charoff="50">0.587<sup>&#x0002a;&#x0002a;&#x0002a;</sup> (0.469)</td><td align="char" valign="top" char="&#x02212;" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">0.588<sup>&#x0002a;&#x0002a;&#x0002a;</sup> (0.510)</td><td align="char" valign="top" char="&#x02212;" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Cw&#x0002a;05</italic></td><td align="char" valign="top" char="(" charoff="50">0.194<sup>&#x0002a;</sup> (0.091)</td><td align="char" valign="top" char="(" charoff="50">0.403<sup>&#x0002a;&#x0002a;&#x0002a;</sup> (0.160)</td><td align="char" valign="top" char="&#x02212;" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">0.002 (0.001)</td><td align="char" valign="top" char="(" charoff="50">&#x02212;0.003 (0.015)</td><td align="char" valign="top" char="&#x02212;" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>DRB1&#x0002a;15</italic></td><td align="char" valign="top" char="(" charoff="50">&#x02212;0.011<sup>&#x0002a;&#x0002a;</sup> (0.074)</td><td align="char" valign="top" char="(" charoff="50">&#x02212;0.014<sup>&#x0002a;&#x0002a;</sup> (0.082)</td><td align="char" valign="top" char="(" charoff="50">&#x02212;0.001 (0.012)</td><td align="char" valign="top" char="&#x02212;" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">&#x02212;0.006 (0.028)</td><td align="char" valign="top" char="(" charoff="50">&#x02212;0.003 (0.011)</td><td align="char" valign="top" char="(" charoff="50">&#x02212;0.003 (0.031)</td><td align="center" valign="top" charoff="50">&#x02212;</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><label/><p>Abbreviation: MS, multiple sclerosis.</p></fn><fn id="t3-fn2"><label/><p>Numbers represent D&#x02032; (Lewontin's delta) and <italic>r</italic><sup>2</sup> (in brackets) values.</p></fn><fn id="t3-fn3"><label/><p><sup>&#x0002a;</sup><italic>P</italic>&#x0003c;0.05, <sup>&#x0002a;&#x0002a;</sup><italic>P</italic>&#x0003c;0.005 and <sup>&#x0002a;&#x0002a;&#x0002a;</sup><italic>P</italic>&#x0003c;0.000001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Phenotypic combinations of <italic>HLA-A&#x0002a;02</italic> and <italic>HLA-Cw&#x0002a;05</italic> in MS patients and controls</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="center"/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>A&#x0002a;02</italic></th><th align="center" valign="top" charoff="50"><italic>Cw&#x0002a;05</italic></th><th align="center" valign="top" charoff="50"><italic>Sample</italic></th><th colspan="2" align="center" valign="top" char="." charoff="50"><italic>Frequency</italic></th><th align="center" valign="top" charoff="50">P<italic>-value</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>OR (95&#x00025; CI)</italic></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="char" valign="top" char="." charoff="50"><italic>Cases</italic></th><th align="char" valign="top" char="." charoff="50"><italic>Controls</italic></th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="char" valign="top" char="(" charoff="50">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50"><italic>Total</italic></td><td align="char" valign="top" char="." charoff="50">N<italic>=1273</italic></td><td align="char" valign="top" char="." charoff="50">N<italic>=1075</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.599</td><td align="char" valign="top" char="." charoff="50">0.513</td><td align="center" valign="top" charoff="50">2.4 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="char" valign="top" char="(" charoff="50">1.42 (1.21&#x02013;1.68)</td></tr><tr><td align="left" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.031</td><td align="char" valign="top" char="." charoff="50">0.078</td><td align="center" valign="top" charoff="50">4.1 &#x000d7; 10<sup>&#x02212;7</sup></td><td align="char" valign="top" char="(" charoff="50">0.38 (0.26&#x02013;0.56)</td></tr><tr><td align="left" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.299</td><td align="char" valign="top" char="." charoff="50">0.370</td><td align="center" valign="top" charoff="50">2.8 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="char" valign="top" char="(" charoff="50">0.73 (0.61&#x02013;0.86)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.070</td><td align="char" valign="top" char="." charoff="50">0.039</td><td align="center" valign="top" charoff="50">0.001</td><td align="char" valign="top" char="(" charoff="50">1.85 (1.27&#x02013;2.69)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50"><italic>DR15 negative</italic></td><td align="char" valign="top" char="." charoff="50">N<italic>=883</italic></td><td align="char" valign="top" char="." charoff="50">N<italic>=935</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.589</td><td align="char" valign="top" char="." charoff="50">0.498</td><td align="center" valign="top" charoff="50">1.1 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="char" valign="top" char="(" charoff="50">1.44 (1.20&#x02013;1.73)</td></tr><tr><td align="left" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.031</td><td align="char" valign="top" char="." charoff="50">0.081</td><td align="center" valign="top" charoff="50">1.8 &#x000d7; 10<sup>&#x02212;6</sup></td><td align="char" valign="top" char="(" charoff="50">0.36 (0.23&#x02013;0.56)</td></tr><tr><td align="left" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.303</td><td align="char" valign="top" char="." charoff="50">0.383</td><td align="center" valign="top" charoff="50">3.6 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="char" valign="top" char="(" charoff="50">0.70 (0.58&#x02013;0.85)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.077</td><td align="char" valign="top" char="." charoff="50">0.038</td><td align="center" valign="top" charoff="50">2.4 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="char" valign="top" char="(" charoff="50">2.15 (1.41&#x02013;3.26)</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><label/><p>Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p content-type="table-title">Distribution of the phenotypic combinations of <italic>HLA-A&#x0002a;02</italic> and <italic>HLA-Cw&#x0002a;05</italic> in MS patients and controls among <italic>DRB1&#x0002a;03</italic>-positive and <italic>DRB1&#x0002a;03</italic>-negative individuals</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><italic>A&#x0002a;02</italic></th><th align="center" valign="top" charoff="50"><italic>Cw&#x0002a;05</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>Cases</italic> N <italic>(&#x00025;)</italic></th><th align="char" valign="top" char="(" charoff="50"><italic>Controls N (&#x00025;)</italic></th><th align="char" valign="top" char="." charoff="50"><italic>OR</italic></th><th align="char" valign="top" char="." charoff="50"><italic>95&#x00025; CI</italic></th><th align="char" valign="top" char="." charoff="50">P<italic>-value</italic></th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>DRB1&#x0002a;03&#x0002b;</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="char" valign="top" char="(" charoff="50">20 (0.19)</td><td align="char" valign="top" char="(" charoff="50">10 (0.06)</td><td align="char" valign="top" char="." charoff="50">3.89</td><td align="char" valign="top" char="." charoff="50">1.74&#x02013;8.66</td><td align="char" valign="top" char="." charoff="50">0.0006</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">57 (0.54)</td><td align="char" valign="top" char="(" charoff="50">82 (0.46)</td><td align="char" valign="top" char="." charoff="50">1.34</td><td align="char" valign="top" char="." charoff="50">0.83&#x02013;2.18</td><td align="char" valign="top" char="." charoff="50">NS</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="char" valign="top" char="(" charoff="50">5 (0.05)</td><td align="char" valign="top" char="(" charoff="50">26 (0.15)</td><td align="char" valign="top" char="." charoff="50">0.28</td><td align="char" valign="top" char="." charoff="50">0.11&#x02013;0.77</td><td align="char" valign="top" char="." charoff="50">0.006</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">24 (0.23)</td><td align="char" valign="top" char="(" charoff="50">59 (0.33)</td><td align="char" valign="top" char="." charoff="50">0.59</td><td align="char" valign="top" char="." charoff="50">0.33&#x02013;1.01</td><td align="char" valign="top" char="." charoff="50">NS</td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><italic>DRB1&#x0002a;03&#x02212;</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="char" valign="top" char="(" charoff="50">16 (0.04)</td><td align="char" valign="top" char="(" charoff="50">26 (0.04)</td><td align="char" valign="top" char="." charoff="50">0.96</td><td align="char" valign="top" char="." charoff="50">0.51&#x02013;1.81</td><td align="char" valign="top" char="." charoff="50">NS</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">274 (0.60)</td><td align="char" valign="top" char="(" charoff="50">360 (0.51)</td><td align="char" valign="top" char="." charoff="50">1.46</td><td align="char" valign="top" char="." charoff="50">1.15&#x02013;1.86</td><td align="char" valign="top" char="." charoff="50">0.002</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="char" valign="top" char="(" charoff="50">13 (0.03)</td><td align="char" valign="top" char="(" charoff="50">49 (0.07)</td><td align="char" valign="top" char="." charoff="50">0.39</td><td align="char" valign="top" char="." charoff="50">0.21&#x02013;0.74</td><td align="char" valign="top" char="." charoff="50">0.002</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x0002b;</td><td align="center" valign="top" charoff="50">&#x02212;</td><td align="char" valign="top" char="(" charoff="50">153 (0.34)</td><td align="char" valign="top" char="(" charoff="50">276 (0.39)</td><td align="char" valign="top" char="." charoff="50">0.79</td><td align="char" valign="top" char="." charoff="50">0.62&#x02013;1.01</td><td align="char" valign="top" char="." charoff="50">NS</td></tr></tbody></table><table-wrap-foot><fn id="t5-fn1"><label/><p>Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio; NS, not significant.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 